1-7 of 7
Michael Keating
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases

Maher Albitar, Wanlong Ma, Susan O'Brien, Iman Jilani, Xi Zhang, Hagop Kantarjian, Zeev Estrov, Michael Keating, Francis Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): B52.
Published: 15 August 2014
View article titled, Enzymatic activity of free circulating proteasomes as biomarkers for predicting clinical behavior in hematologic diseases
Journal Articles

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

Wanlong Ma, Hagop Kantarjian, Benjamin Bekele, Amber C. Donahue, Xi Zhang, Zhong J. Zhang, Susan O'Brien, Elihu Estey, Zeev Estrov, Jorge Cortes, Michael Keating, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (11): 3820–3826.
https://doi.org/10.1158/1078-0432.CCR-08-3034
Published: 01 June 2009
View article titled, Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
Open the PDF for Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome in another window
Includes: Supplementary data
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia

Jessica C. Pahler, Stacey Ruiz, Irina Niemer, Leslie R. Calvert, Michael Andreeff, Michael Keating, Stefan Faderl, David J. McConkey
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (12): 4570–4577.
Published: 10 October 2003
View article titled, Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia
Open the PDF for Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia in another window
Journal Articles

Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate

Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortes, Terry L. Smith, Mary Beth Rios, Jianqin Shan, Ying Yang, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Guillermo Garcia-Manero, Sima Jeha, William Wierda, Jean-Pierre J. Issa, Steven M. Kornblau, Michael Keating, Debra Resta, Renaud Capdeville, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2167–2176.
Published: 01 July 2002
View article titled, Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate
Open the PDF for Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate in another window
Journal Articles

Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: Follow-Up Results

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Terry L. Smith, Francis J. Giles, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia-Manero, Jean-Pierre J. Issa, Michael Andreeff, Steven M. Kornblau, Charles Koller, Milosav Beran, Michael Keating, Mary Beth Rios, Jenny Shan, Debra Resta, Renaud Capdeville, Kimberly Hayes, Maher Albitar, Emil J. Freireich, Jorge E. Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2177–2187.
Published: 01 July 2002
View article titled, Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle>
Open the PDF for Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle> in another window
Journal Articles

Persistence of Peripheral Blood and Bone Marrow Blasts during Remission Induction in Adult Acute Lymphoblastic Leukemia Confers a Poor Prognosis Depending on Treatment Intensity

Jorge Cortes, Luis Fayad, Susan O’Brien, Michael Keating, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2491–2497.
Published: 01 September 1999
View article titled, Persistence of Peripheral Blood and Bone Marrow Blasts during Remission Induction in Adult Acute Lymphoblastic Leukemia Confers a Poor Prognosis Depending on Treatment Intensity
Open the PDF for Persistence of Peripheral Blood and Bone Marrow Blasts during Remission Induction in Adult Acute Lymphoblastic Leukemia Confers a Poor Prognosis Depending on Treatment Intensity in another window